UNSPSC 51332802: Acepromazine

This classification denotes a dopamine antagonist with the molecular formula C19H22N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 54EJ303F0R, chemically known as promazine, acetyl- but generally known as acepromazine, which bears US NIH Compound Identifier 6077. Acepromazine most often comes in forms base, hydrogen maleate, or maleate. European Medicines Agency schedules Acepromazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05213MIG.

UNSPSC 51332802 Acepromazine, a Commodity code, does not map to the actual work state and local governments are soliciting under this classification. The recent opportunities tagged to this code — Seminole County's procurement of naloxone and drug deactivation systems, the Texas HHS Commission's RFI on direct-to-manufacturer prescriptions, and MMCAP's multistate RFP for generic pharmaceuticals and OTC products — center on naloxone, pharmacy benefit programs, and broad pharmaceutical distribution rather than acepromazine specifically. The code shows little activity directly aligned to its nominal scope as a single tranquilizer compound; instead, jurisdictions and cooperative purchasing alliances are buying finished pharmaceutical products, pharmacy services, and medical countermeasures through health departments, HHS agencies, and state procurement offices.

Recent opportunities span Seminole County (Florida), the Texas Health and Human Services Commission, and Minnesota's MMCAP cooperative purchasing vehicle serving multiple states including Oregon. Seminole County issued IFB 60459723LAS on June 30, 2026 (response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission released RFI HHS0017013 on April 3, 2026 to explore direct-to-manufacturer prescription programs; and MMCAP posted RFP S1070000015802 on January 20, 2026 (response due March 26, 2026) to establish multistate contracts for generic and OTC pharmaceuticals through authorized wholesalers, with awards effective July 1, 2026. The mismatch between the code's chemical specificity and the breadth of pharmaceutical procurement activity suggests the classification may reflect a data-entry or tagging error rather than a meaningful category for business development targeting.